


I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Patent Application, Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28th day of October, 2003.

By



(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Stephen Challenger, et al. :

APPLICATION NO.: To Be Assigned : Examiner:

FILING DATE: Herewith : Group Art Unit:

TITLE: N-PHENPROPYLCYCLOPENTYL- :  
SUBSTITUTED GLUTARAMIDE  
DERIVATIVES AS INHIBITORS OF  
NEUTRAL ENDOPEPTIDASE

Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


In compliance with 37 C.F.R. § 1.98(d), Applicants are not providing a copy of the references "since they were previously cited by and submitted to the Office in a prior application." The prior application entitled "N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE" had U.S. Serial No. 09/096,218 and is the parent of the instant case. In addition, it is relied upon for an earlier filing date under 35 U.S.C. § 120.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: 10/28/03

Respectfully submitted,



A. Dean Olson  
Attorney for Applicant(s)  
Reg. No. 31,185

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 441-4904

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>								<b>ATTY. DOCKET NO.</b> PC10967B				<b>SERIAL NO.</b> To Be Assigned			
								<b>APPLICANT</b> Stephen Challenger, et al.							
								<b>FILING DATE</b> Herewith				<b>GROUP</b>			

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
W	O	9	1	0	7	3	8	6	5/30/91	International	C07C				
W	O	9	1	1	0	6	4	4	7/25/91	International	C07C				
E	P	1	0	9	7	7	1	9	9/5/01	European	A61K				
W	O	9	1	1	3	0	5	4	9/5/01	International	C07C				
W	O	9	4	0	6	7	5	6	3/31/94	International	C07C				
W	O	0	2	0	2	5	1	3	1/10/02	International	C07C				
E	P	0	2	7	4	2	3	4	11/09/91	European	C07C				

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>													

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.